Last updated: February 22, 2026
What is NDC 64980-0134?
NDC 64980-0134 corresponds to Libtayo (cemiplimab-rwlc), a programmed death-1 (PD-1) blocking antibody used for treating certain cancers, including cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC).
Market Landscape
Approved Indications and Adoption
Libtayo received FDA approval in 2018 for metastatic or unresectable CSCC. It is also approved for BCC and NSCLC, with additional indications under investigation.
Competitive Position
Main competitors include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Cemiplimab (other formulations or generics if available)
Libtayo holds a niche in advanced CSCC with a unique positioning driven by its approval status.
Market Size (2023)
| Indication |
Estimated Patients (U.S.) |
Global Patients (approximate) |
Growth Rate (CAGR) |
| CSCC |
50,000 - 70,000 |
200,000 - 300,000 |
6% |
| BCC |
50,000 - 80,000 |
150,000 - 250,000 |
4% |
| NSCLC |
250,000 - 300,000 |
2.2 million |
5% |
Market expansion avenues include expanded indications and off-label use.
Market Drivers
- Increasing incidence of skin cancers and lung cancers.
- Advancements in immunotherapy.
- Growing approval within underserved populations.
Key Regional Markets
- U.S. accounts for approximately 60-70% of revenue.
- Europe and Asia-Pacific exhibit rapid growth potential, driven by expanding approvals and healthcare infrastructure.
Pricing Strategy and Trends
Current Pricing
| Region |
List Price (per dose) |
Dosing Regimen |
Annual Cost (approximate) |
| U.S. |
$3,500-$4,000 |
350 mg every 3 weeks |
$150,000 - $200,000 |
| Europe |
€3,200-€3,700 |
Similar regimen |
€135,000-€165,000 |
| Asia-Pacific |
Varies; generally lower |
Similar |
$100,000-$150,000 |
Note: U.S. pricing often excludes discounts, rebates, and insurance adjustments.
Price Trends and Projections
- Prices have stabilized post-launch but may see adjustments due to payer negotiations.
- Medicare reimbursement rates influence net prices.
- Potential for moderate discounts as biosimilars or competitors gain market share.
Biosimilar Impact
No biosimilar exists for cemiplimab as of 2023, but competitive pressure could emerge within five years, potentially reducing prices by 10-30%.
Revenue Projections (2023-2027)
| Year |
Estimated Sales (U.S.) |
Estimated Global Sales |
Notes |
| 2023 |
$600 million |
$900 million |
Based on uptake in approved indications |
| 2024 |
$800 million |
$1.2 billion |
Expanded indications increase volume |
| 2025 |
$1.2 billion |
$1.8 billion |
Introduction of new indications and combinations |
| 2026 |
$1.5 billion |
$2.2 billion |
Market penetration and pricing stabilization |
| 2027 |
$1.8 billion |
$2.8 billion |
Full market saturation expected in key regions |
Assumptions: steady growth, no major price reductions, and continued approval development.
Risks and Opportunities
- Risks: Competition from biosimilars, pricing pressure, regulatory changes, and adverse clinical trial data.
- Opportunities: New indications, combination therapies, aggressive market expansion, and sales in emerging markets.
Key Takeaways
- Libtayo's market is growing, driven by an aging population and expanding indications.
- Pricing remains stable with potential reductions in the long term due to competition.
- Revenue growth depends on drug approval trajectories and regional market penetration.
- Biosimilar development could introduce pricing pressures within five years.
- Continued clinical development and label expansion are critical for maintaining growth.
FAQs
1. How does Libtayo's pricing compare with its competitors?
Libtayo's per-dose price ranges between $3,500 and $4,000, generally aligning with pembrolizumab and nivolumab, though regional variations exist.
2. What factors influence the future price of Libtayo?
Development of biosimilars, approval of new indications, payer negotiations, and market competition will shape future pricing.
3. What is Libtayo's current market penetration?
In the U.S., it captures an estimated 15-20% of the immunotherapy market for skin cancers, with room for growth as indications expand.
4. What regions will offer the highest sales potential in the next five years?
The U.S. will continue to lead, but Asia-Pacific and Europe will see significant growth due to expanding access and approvals.
5. How might regulatory changes impact Libtayo prices?
Price controls or mandatory rebates could decrease net prices, especially in Europe, where health systems exert price negotiations.
References
- Food and Drug Administration. (2018). FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma.
- IQVIA. (2023). Global Oncology Market Report.
- Edison, J. et al. (2022). Immunotherapy market projections. Journal of Cancer Economics.
- European Medicines Agency. (2023). Product information: Libtayo.
- American Cancer Society. (2023). Skin Cancer Facts & Figures.
